Medtronic Resolves FDA Warning Letters. FDA Approves Cancer Generic Docetaxel. Print E-mail
By BioMedReports.com Staff   
Wednesday, 09 March 2011 19:24

Below is a look at some of the headlines for companies that made news in the healthcare sector on March 09, 2011. Medtronic Resolves FDA Warning Letters - Medtronic Inc. (NYSE:MDT) said it has resolved the U.S. FDA warning letters regarding two of its facilities.  Medtronic Inc. (NYSE:MDT) received an FDA warning letter following an August 2009 inspection of the company's Mounds View facility, and an FDA warning letter following a December 2008 inspection of the company's facility in Juncos.

Today, the FDA has informed Medtronic Inc. (NYSE:MDT) issues regarding the August 2009 and the December 2008 warnings of those two facilities have been resolved.

FDA Approves Hospira's Cancer Generic Docetaxel - Hospira, Inc. (NYSE:HSP), said Wednesday the U.S. Food and Drug Administration has approved docetaxel, a generic version of French healthcare company Sanofi-Aventis' (NYSE:SNY) Taxotere, for the treatment of a variety of cancers.  Hospira expects to launch the product later this month. The company already markets docetaxel in Europe and Australia. In 2010, Taxotere's U.S. sales were approximately $1.2 billion.


Also Wednesday:


Access Plans, Inc. (OTCQB: APNC) (PINKSHEETS: APNC), a leading membership benefits marketing company, today announced that trading in its common shares has migrated from the OTCBB quotation and trading system to the OTC Markets Group, Inc. quotation and trading system.

Corcept Therapeutics Incorporated (NASDAQ:CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported financial results for the fourth quarter ended December 31, 2010, and updated its corporate progress.

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced that Efri Argaman, the Company's Chief Executive Officer, will present an update on the Company's business at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference on Wednesday, March 16, 2011 at 9:00 a.m. Pacific Time.

Digirad Corporation (NASDAQ: DRAD) today reported fourth quarter revenue of $14.7 million, 2010 full-year revenue of $56.2 million and an ending cash and available-for-sale securities balance of $30.2 million at December 31, 2010.

Elysium Internet, Inc. DBA www.TheDirectory.com (PINKSHEETS: EYSM), an emerging leader in the Local Business Search Market, today announced that just 9 days into the month of March it has booked 50% of the revenue generated for the entire month of February.

Genomic Health, Inc. (NASDAQ: GHDX), in partnership with Fight Colorectal Cancer, today introduced My Colon Cancer Coach, a unique online tool that provides patients with apersonalized report of their specific type of colon cancer.

Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Officethat Lpath has been issued a key patent to add to its expanding patent portfolio, which has grown now by five patents over the last six months.

Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, published an in-depth interview with Jeffrey Gottfurcht, founder of the Jeffrey Gottfurcht Children's Arthritis Foundation (JGCAF).

D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED)
("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced financial results for the quarter and year ended December 31, 2010.

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter